Back in March, the Second Sight Medical Products (NASDAQ: EYES) stock was in considerable focus among investors as it went on a remarkable run. However, eventually, the stock declined just as sharply.
On Tuesday, the Second Sigh stock seemed to be back in focus among investors and regained strong momentum to record gains of as big as 27.50%. There was no news with regards to the company on Tuesday, but it might be useful for investors to take a look at development from last month. Back in March, the company got a major boost after the United States Food and Drug Administration approved the retinis Pigmentosa treatment from Second Sight.
The development took place back on March 9 and soon enough the Second Sight stock started rallying strongly. While the stock did eventually correct, the fact that it has regained its momentum yet again might bring Second Sight back into the radars of investors this week.
CEO and Editor in Chief.
Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life